The mutagenic activity of razoxane (ICRF 159): an anticancer agent.

The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays. Razoxane (up to 5000 micrograms/plate) did not cause an increase in the mutation frequency in the Salmonella/microsome assay. In the mouse micronuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Albanese, R., Watkins, P. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977223/
https://www.ncbi.nlm.nih.gov/pubmed/3904803
_version_ 1782135215894822912
author Albanese, R.
Watkins, P. A.
author_facet Albanese, R.
Watkins, P. A.
author_sort Albanese, R.
collection PubMed
description The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays. Razoxane (up to 5000 micrograms/plate) did not cause an increase in the mutation frequency in the Salmonella/microsome assay. In the mouse micronucleus assay razoxane (200 and 400 mg kg-1 i.p.) was cytotoxic to the bone marrow cells (which limited the analysis) but an increase in micronucleated polychromatic erythrocytes was observed in razoxane dosed animals (5-fold compared to control value). In the Chinese hamster metaphase assay razoxane (up to 500 mg kg-1 orally) induced abnormal chromosome condensation and an increase in structural chromosome aberrations (7 fold compared to control value) as well as an increase in the number of polypoid cells (8-fold compared to control value). The mutagenic effect of razoxane was restricted to eukaryotic organisms and was associated with specific chromosomal changes. IMAGES:
format Text
id pubmed-1977223
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19772232009-09-10 The mutagenic activity of razoxane (ICRF 159): an anticancer agent. Albanese, R. Watkins, P. A. Br J Cancer Research Article The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays. Razoxane (up to 5000 micrograms/plate) did not cause an increase in the mutation frequency in the Salmonella/microsome assay. In the mouse micronucleus assay razoxane (200 and 400 mg kg-1 i.p.) was cytotoxic to the bone marrow cells (which limited the analysis) but an increase in micronucleated polychromatic erythrocytes was observed in razoxane dosed animals (5-fold compared to control value). In the Chinese hamster metaphase assay razoxane (up to 500 mg kg-1 orally) induced abnormal chromosome condensation and an increase in structural chromosome aberrations (7 fold compared to control value) as well as an increase in the number of polypoid cells (8-fold compared to control value). The mutagenic effect of razoxane was restricted to eukaryotic organisms and was associated with specific chromosomal changes. IMAGES: Nature Publishing Group 1985-11 /pmc/articles/PMC1977223/ /pubmed/3904803 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Albanese, R.
Watkins, P. A.
The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
title The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
title_full The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
title_fullStr The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
title_full_unstemmed The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
title_short The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
title_sort mutagenic activity of razoxane (icrf 159): an anticancer agent.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977223/
https://www.ncbi.nlm.nih.gov/pubmed/3904803
work_keys_str_mv AT albaneser themutagenicactivityofrazoxaneicrf159ananticanceragent
AT watkinspa themutagenicactivityofrazoxaneicrf159ananticanceragent
AT albaneser mutagenicactivityofrazoxaneicrf159ananticanceragent
AT watkinspa mutagenicactivityofrazoxaneicrf159ananticanceragent

Ejemplares similares